Last Updated: 15/07/2022

VivAccess: A Market Manager for Optimizing Plasmodium vivax Radical Cure

Objectives

To facilitate access to Plasmodium vivax safe radical-cure product packages, including new products, in priority countries.

Specific Objectives

  1. Coordinate global strategy for introduction and scale of vivax products.
  2. Package of P. vivax  diagnostics and drugs registered, procured, and available in 15 priority countries, including primaquine, tafenoquine, quantitative G6PD diagnostics, and improved P. vivax diagnostics.
Principal Investigators / Focal Persons

Nicholas Luter
George Jagoe

Thematic Categories

P. vivax

Date

Nov 2018 — Jan 2024

Total Project Funding

$15M

Funding Details
SHARE
SHARE